Skip to main content

Table 2 Demographic and baseline parameters of the study population

From: Implementation of continuous renal replacement therapy with regional citrate anticoagulation on a surgical and trauma intensive care unit: impact on clinical and economic aspects—an observational study

Parameter CVVHD—citrate CVVHDF—heparin p value
Number of patients (n) 60 50  
Gender (n, male) 44 (73 %) 36 (72 %) n.s.
Age (years) 68 ± 12 69 ± 11 n.s.
Bodyweight (kg) 87 ± 21 86 ± 23 n.s.
Sepsis (n) 16 (27 %) 16 (32 %) n.s.
Postoperative (n) 40 (66 %) 25 (50 %) n.s.
Other reason for ICU admission (n) 4 (7 %) 9 (18 %) n.s.
SOFA score at initiation of CRRT 10 ± 3 9 ± 3 n.s.
Creatinine before present illness (μmol/l) 195 ± 139 226 ± 252 n.s.
Creatinine at initiation of CRRT (μmol/l) 337 ± 133 343 ± 179 n.s.
Urea before present illness (mmol/l) 11 ± 9 10 ± 9 n.s.
Urea at initiation of CRRT (mmol/l) 23 ± 9 22 ± 9 n.s.
Mean platelet count during CRRT (G/l) 168 ± 108 175 ± 115 n.s.
Mean dose of CRRT (ml∙h−1∙kg body weight−1) 24.0 ± 6.2 20.7 ± 5.6 0.0001
Mean blood flow (ml/min) 102 ± 12.5 100 ± 2.8 n.s.
Mean dialysate flow (ml/h) 2035 ± 307 1133 ± 283 0.0001
Mean flow replacement fluid (ml/h) 563 ± 203 n.a.
Mean ultrafiltration flow (ml/h) 159 ± 55 170 ± 59 0.0001
Mechanical ventilation (n) 43 (72 %) 40 (80 %) n.s.
Cirrhosis of the liver (n) 6 (10 %) 4 (8 %) n.s.
Patients weaned from CRRT (n) 22 (37 %) 19 (38 %) n.s.
Patients receiving intermittent dialysis at ICU discharge (n) 8 (13 %) 4 (8 %) n.s.
Fatal outcome on ICU (n) 30 (50 %) 27 (54 %) n.s.
  1. CRRT continuous renal replacement therapy, CVVHDF continuous veno-venous haemodiafiltration, CVVHD continuous veno-venous haemodialysis, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, n.s. not significant, n.a. not applicable